Bleeding Risk: Anticoagulant Stacking

Anticoagulant stacking refers to the concurrent use of multiple antithrombotic agents — anticoagulants, antiplatelets, and/or fibrinolytics — that amplify bleeding risk through additive or synergistic inhibition of hemostatic pathways. The NP must understand where each drug class acts in the coagulation cascade to predict cumulative bleeding risk. Primary hemostasis (platelet plug formation): Vascular injury exposes subendothelial collagen and von Willebrand factor (vWF). Platelets adhere (glycoprotein Ib binding to vWF), activate (releasing ADP, thromboxane A2, and serotonin from dense granules), and aggregate (glycoprotein IIb/IIIa cross-linking via fibrinogen bridges). Antiplatelet agents disrupt this: aspirin irreversibly inhibits COX-1 (blocking thromboxane A2 synthesis for the platelet's 7-10 day lifespan); P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) block ADP-mediated platelet activation; GP IIb/IIIa inhibitors (abciximab, eptifibatide) block the final common pathway of platelet aggregation. Secondary hemostasis (fibrin clot formation): The coagulation cascade generates thrombin (factor IIa) via the intrinsic and extrinsic pathways, which converts fibrinogen to fibrin. Anticoagulants act here: warfarin inhibits vitamin K-dependent synthesis of factors II, VII, IX, X and proteins C and S; heparins (UFH, LMWH) activate antithrombin III to inhibit thrombin and factor...